Connect with us

Health

Valo Therapeutics Acquires University of Helsinki’s PeptiBAC Cancer and Infectious Disease Vaccination Technology – PRNewswire

/PRNewswire/ — Valo Therapeutics Limited (Valo Tx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today…

Published

on

HELSINKI, April 19, 2021 /PRNewswire/ — Valo Therapeutics Limited (Valo Tx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced the acquisition of intellectual property rights for the proprietary ‘PeptiBAC’ technology from the University of Helsinki, Finland.
PeptiBAC uses the BCG (Bacillus Calmette-Guèrin) vaccine as a backbone for delivery of disease specific peptides. The technology has preventative potential in infectious diseases,…

Click here to view the original article.

You might also like ...

Article feature image
How accurate were early expert predictions on COVID-19, and how did they compare to the public? – EurekAlert
Article feature image
U.S. administers 249.6 mln doses of COVID-19 vaccines – CDC – Reuters
Article feature image
Sugar Coated Brain Implants – Medgadget